Researchers in Japan have reported a significant step in the long‑standing scientific effort to develop an insulin medication ...

For decades, science has chased a simpler way to deliver life—seeking to turn needles into something as easy as a pill. Breaking the Barrier: A New Path for Insulin For over a century, researchers ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...

Danish pharma major Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec ...

The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the appointment of Mike ...

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available ...

Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. Click here to read an ...

Eli Lilly announced this morning that the FDA has, as was expected, approved its oral GLP-1, orforglipron, as treatment for ...